Corgenix and NIH in liver test pact:
This article was originally published in Clinica
Executive Summary
Corgenix Medical has struck a deal with the US National Institutes of Health (NIH) to develop a test for the liver disease non-alcoholic steatohepatitis (NASH). The corporative research and development agreement (CRADA) will use Corgenix's hyaluronic acid (HA) test kit in combination with other liver fibrosis biomarkers to develop a test for NASH - a form of non-alcoholic fatty liver disease (NAFLD). Currently the only way to distinguish NASH from NAFLD is to run a highly invasive liver biopsy test; differentiating the two is important since the conditions have different prognoses, said the Denver, Colorado based company. Some 65-75 million Americans currently suffer from NAFLD.